Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05516927 · ClinicalTrials.gov registry record
The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
A clinical trial, sponsored by Freenome Holdings.
- Completed
- Registry status
- 788
- Enrollment target
NCT05516927: Completed study, sponsored by Freenome Holdings.
NCT05516927 is a clinical trial that has completed, run by Freenome Holdings. The registered enrollment target is 788 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05516927 has completed, sponsored by Freenome Holdings.
- COMPLETED
- Registry status
- 788 participants
- Enrollment target
Study Summary
This protocol is a prospective, case-control multi-center diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.
Primary Outcome
To compare blood samples from cancer case and non-cancer control subjects in order to develop and characterize blood-based multiomics tests in specific cancer types or in a combination of multiple cancers.
Interventions
- DIAGNOSTIC_TEST Freenome Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 788 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2024-05-02 |
What the finished NCT05516927 record still lists
NCT05516927 is an observational study that tracks outcomes without assigning an intervention. The registered 788 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Freenome Test is the first listed.
NCT05516927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05516927 about?
NCT05516927 is a clinical study titled "The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening". This protocol is a prospective, case-control multi-center diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.
What is the current status of trial NCT05516927?
This trial is currently completed. The enrollment target is 788 participants. The study started on 2022-09-06. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT05516927?
The interventions under investigation include: Freenome Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05516927?
This trial is sponsored by Freenome Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI